There have been numerous reports describing effects of IL-4 on bone biology. Previous studies, performed using complex co-culture systems, demonstrated effects of IL-4 on both osteoblasts and osteoclasts. To directly test the effect of IL-4 on osteoclasts, we took advantage of a simplified system using recombinant RANKL as the osteoclast differentiation factor. We analyzed the ability of IL-4 to directly regulate osteoclast differentiation and mature osteoclast function. We found that IL-4 inhibited the differentiation of osteoclasts from bone marrow precursors in an irreversible manner and also inhibited the resorptive capacity of mature osteoclasts. In the presence of IL-4 we detected the appearance of TRAP negative mutinucleated giant cells (MNG). Both IL-4 effects were dependent upon STAT6. We found that IL-4 suppresses RANK mRNA expression in the developing precursor cells. When RANK was ectopically expressed under the CMV promoter in RAW264.7 macrophages, IL-4 treatment did not inhibit osteoclast development. Furthermore, when osteoclastogenesis was induced independently of RANKL by using TNF , IL-4 inhibited osteoclast differentiation through a STAT6 dependent mechanism. These results suggest that IL-4 regulates osteoclast development by regulating gene expression including RANK. We propose that IL-4 irreversibly regulates the lineage commitment of precursor cells by regulating gene expression resulting in the suppression of osteoclast development and the generation of MNG as an alternative pathway of differentiation.
INTRODUCTION
Cells of the monocyte-macrophage lineage derived from hematopoietic progenitors are able to differentiate into several cell types with markedly distinct morphological and functional characteristics depending on the extracellular environment. [1] [2] [3] Some of these cell types are mononuclear such as dendritic cells and mononuclear macrophages while others are multinucleated. Among the multinucleated type there are multinucleated giant cells (MNG) and osteoclasts. 3 Although they share a common origin, the signals involved in their differentiation, the spectrum of expressed genes, and their biological functions are markedly distinct.
In several of these cell types, the immune cytokine IL-4 plays a critical role in regulating their differentiation and/or activity.
lines and in normal lymphocytes. The IL-4-induced activation of STAT6 has been shown to be critical for regulation of gene expression, development of IgE producers from Bcells, and efficient TH2 development in response to protein antigens. 11 Over the last 10 years, there have been numerous reports describing an effect of IL-4 on bone biology. Initially experiments were performed in vivo or by using a complex in vitro co-culture system consisting of stromal cells and bone marrow precursors. 6, 8, [15] [16] [17] [18] [19] [20] [21] [22] It was found that IL-4 could have potent effects on both the osteoblast and the osteoclast, indicating that IL-4 could play a complex role in regulating bone homeostasis. From that first general observation of the IL-4 inhibition of bone resorption 6 , to the establishment of the osteoclast precursor as the ultimate target of the IL-4 effect 8 , the limitation of having to employ co-culture systems has hindered further advances in clarifying the mechanism by which IL-4 regulates osteoclast differentiation and function. The discovery of RANKL, a member of the tumor necrosis factor (TNF) cytokine superfamily, and its role in the bone and immune systems has further clarified the mechanism by which IL-4 regulates bone biology. [23] [24] [25] [26] [27] Two recent reports 5, 7 demonstrated that IL-4 was able to directly suppress the development of osteoclasts from bone-marrow precursors induced by RANKL. This IL-4-induced suppression was dependent upon STAT6. These studies also provided some data suggesting that IL-4
inhibited RANKL-activated signaling, including NF-B activation. 5, 7 One of these reports concluded that the IL-4 inhibition of osteoclastogenesis was reversible 5 , while the other came to the opposite conclusion. 7 The ability of IL-4 to directly suppress NF-B activation per se is controversial and in many cases IL-4 enhances NF-B activation depending on the cell type.
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For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From Therefore, we analyzed the ability of IL-4 to directly regulate osteoclast differentiation and mature osteoclast function in several different cell systems. In contrast to a previous report 5 , we found that IL-4 inhibited the differentiation of osteoclasts from bone-marrow precursors in an irreversible manner. Furthermore, we found that IL-4 was able to directly inhibit the resorptive capacity of mature osteoclasts in a stromal cell-free culture system. The effects of IL-4 on both osteoclast differentiation and function of mature osteoclasts were dependent upon STAT6. The IRS pathway was not activated in immature or mature osteclasts by IL-4. We further provide direct evidence that IL-4 suppresses osteoclast differentiation in part through the regulation of RANK expression.
MATERIALS AND METHODS

Isolation of osteoclast precursors from different sources
Human mononuclear cells were collected from whole blood buffy coats from consented healthy volunteers donors (according to acceptable guidelines from the Institutional Review Board), and CD14 + monocytes were immunoselected (Miltenyi, Minnesota). These cells were plated in the presence of rhM-CSF for three days prior to use in osteoclast differentiation assays.
For the murine experiments, nonadherent bone marrow mononuclear cells were isolated from femurs and tibias of four to six weeks old wild type Balb/c and STAT6 -/-female mice (The Jackson Laboratory, Bar Harbor, ME). Cells were cultured overnight in -10 media to deplete adherent stromal cells followed by isolation of the mononuclear cells over ficoll-hypaque density gradients as described before.
29 These non-adherent bone marrow mononuclear cells were cultured for three days in the presence of 20 ng/ml recombinant mouse M-CSF (rmM-CSF) (R&D systems Inc.) to generate osteoclast precursors (here after also called BMM).
Osteoclast differentiation in vitro
Human or murine osteoclast precursor cells were plated at 1 x 10 6 cells/ml in -10 in the presence of 20 ng/ml of recombinant M-CSF (R&D systems Inc.) and RANKL (150 ng/ml of recombinant mouse RANKL-thioredoxin fusion protein, produced in our laboratory 
Osteoclast generation with TNF-
For these experiments, osteoclasts progenitors were treated as described elsewhere. 30 Briefly, osteoclast precursors were plated in -10 in the presence of 100 ng/ml of rmM-CSF for the first 3 days. Nonadherent cells were completely removed from the culture, and the adherent cells were cultured for an additional 3 days in 100 ng/ml of rmM -CSF and 20 ng/ml of recombinant mouse TNF-(rmTNF-) (R&D systems) or 150 ng/ml of RANKL +/-10 ng/ml of recombinant mouse IL-4 (rmIL-4) (R&D systems).
At the end of the 6 day culture period, the cells were subjected to TRAP staining.
Isolation of mature osteoclast from collagen films and bone resorption assays
The method for the purification of mature osteoclast from collagen films was adapted from a previous protocol. 31, 32 Briefly, osteoclast precursors were plated in culture plates coated with a type I collagen film (Vitrogen 100, Cohesion, Palo Alto, California).
Cells were fed with fresh -10, rmM-CSF (20ng/ml) (R&D systems) and RANKL (150ng/ml) every other day. After six days in culture the plates were washed with PBS and then the collagen film was digested with a solution of 0.2% collagenase A (Boehringer Mannheim GmbH, Mannheim, Germany). The cells were harvested by centrifugation, washed and resuspended in fresh complete -10 and plated on hydroxyapatite coated glass (OSTEOLOGIC TM analysis discs, BD Biosciences, Bedford, MA) or on dentin slices. At the time of seeding on dentin or hydroxyapatite discs, rmM-CSF (20ng/ml) (R&D systems) and RANKL (150ng/ml) plus 10 ng/ml of rmIL-4 (R&D systems) in PBS or control vehicle (PBS) was added to the cultures. After 24 or 48 hours of incubation, the discs were washed in 5% sodium hypochlorite for 5 minutes to remove 
Signaling experiments
Cells were deprived of serum for 4 hours previous to the addition of 10 ng/ml of rmIL-4 (R&D systems) for 10 minutes. Subsequently, the cells were lysed in lysis buffer (50 mM pH 8.0 Tris 150 mM Na Cl 1% NP-40 5 mM EDTA 10 mM Na pyrophosphate 50 mM Na F 0.25% Na deoxycholate 1 mM Na orthovanadate 1 mM PMSF, Pepstatin, Leupeptin and Aprotinin) and clarified by centrifugation. Protein concentration was 
RT-PCR Analysis
Total RNA was isolated from bone marrow cells using an Rneasy Mini Kit The conditions for the a Light-Cycler reactions for both genes were: denaturation at 95°C for 2 seconds; annealing at 60°C for 5 seconds; extension at 72°C for 45 seconds; 45 cycles.
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Flow Cytometry
Surface expression of RANK protein on osteoclast progenitors was measured by FACS analysis using fluorescen-conjugated (FITC-)RANKL as previously described. 34 Murine osteoclast precursors were cultured under various experimental conditions. Aliquots of 1x sequences derived from RANK cDNA). These primers introduced an AscI site followed by a myc-tag (recognition sequence for antibody 9E10) followed by a HindIII site at the 5' end of the cDNA , and a NotI and an EcoRI site at its 3' end such that the entire AscINotI fragment could be inserted in the correct reading frame into the pSECTAG-2a
For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From mammalian expression vector (Invitrogen). With this cloning strategy, the RANK cDNA is expressed from the CMV promoter of pSECTAG, and the signal peptide, derived from Ig -chain leader sequence is also provided by the vector. The signal peptide is followed by the myc-tag followed by the entire mature mouse RANK protein sequence. Therefore the expressed RANK protein is distinguishable from the endogenous protein by the presence of the myc-tag. RAW 264.7 cells were transfected with this RANK construct by Lipofectamine (Invitrogen) according to manufacturer's instructions. Subsequently, the cells were diluted, in media containing 300 µg/ml hygromycin (Invitrogen) to an average density of 0.5 cell per well of 96 well microtiter plates to ensure isolation of clonal lines.
Antibiotic resistant clones were assayed for the presence of ectopic RANK expression by immunoblots using the 9E10 anti-myc monoclonal antibody for detection. Two RANK over expressing clonal lines, herein referred to as clones 1 and 2, were used for osteoclastogenesis assays in the presence or absence of IL-4.
RESULTS
IL-4 inhibits osteoclast differentiation from human and murine precursor cells.
The T-cell derived cytokine IL-4 has been reported to affect both osteoblasts and osteoclasts. 6, 8, [15] [16] [17] [18] [19] 22, 35 Recently, it has been shown that IL-4 induced suppression of osteoclast development is dependent upon STAT6 expression. 5, 7 To fully delineate the mechanism by which IL-4 regulates osteoclast development and function, we used three 
IL-4 inhibits the bone resorption activity of mature osteoclasts.
In addition to the ability of IL-4 to inhibit in vitro osteoclast formation from human and murine progenitors, we also investigated whether IL-4 was able to regulate the resorbing activity of the mature osteoclast. We focused on the murine system because of the easy access to the cells and to reduce the heterogeneity in age and variability between individual donors. Bone marrow cells from wild type mice were plated on collagen films in the presence of M-CSF and RANKL for 6 days, at which time they 
Mechanism of IL-4 action
Since IL-4 inhibited the differentiation of osteoclast progenitors as well as the activity of mature osteoclasts, we analyzed IL-4 signaling in BMM precursors and mature cells. It is well known in other systems, that IL-4 activates two major signaling pathways, namely STAT6 and IRS. 11 We determined the activation status of these signal transducers in response to IL-4 in osteoclast progenitors and mature osteoclasts ( Figure   3 ). As shown in figure 3A , IL-4 stimulation of osteoclast progenitors as well as mature osteoclasts resulted in tyrosine phosphorylation of STAT6. The relative amount of STAT6 protein present in the progenitors and in the mature cells was similar. Next, we 37 We applied the same methodology for IRS2 as in the previous experiments with STAT6. Despite numerous attempts, we did not detect IRS2
phosphorylation following IL-4 stimulation of mature osteoclasts or their precursors ( Figure 3B) . Surprisingly, analysis of the protein blots showed that osteoclast precursors express very low levels of IRS2 protein, although its expression is readily detectable in mature osteoclasts ( Figure 3B ). Insulin and IGF-1 are known to signal by activating IRS proteins. As a positive control we stimulated mature osteoclasts with insulin, followed by IRS2 immunoprecipitation and phosphotyrosine immunoblot. As expected, IRS2 became phosphorylated indicating that there is no inherent anomaly in the cells to signal through the IRS pathway ( Figure 3C ). We also routinely tested the activity of our IL-4 (and 38
Dose Response to IL-4
We tested the sensitivity of the precursor cells by adding increasing amounts of rmIL-4 to the cultures keeping the concentrations of M-CSF and RANKL at optimal levels. As shown in Figure 4A , as little as 1 ng/ml of IL-4 completely blocked (Figure 1 C) . These data are consistent with the notion that during this For
IL-4 inhibits surface expression of RANK receptor.
To analyze the cell surface expression of RANK and to enumerate the RANK positive (RANK + ) osteoclast precursors under various conditions, we used FITC-RANKL as previously described 34 
IL-4 fails to inhibit osteoclastogenesis in RANK over-expressing cells
To directly test whether IL-4 suppresses osteoclast development by inhibiting the 
TNF osteoclastogenesis
Recently it has been shown that osteoclastogenesis promoted by TNF is independent of RANKL-induced signaling. 30 We cultured osteoclast progenitors from wild type and STAT6 -/-animals with 100 ng/ml of M-CSF for three days, after which we added either TNF (20ng/ml), or TNF and IL-4 (10ng/ml) to the cultures for the (A) BMMs were isolated from wild type mice and differentiated to osteoclasts by culturing with rmM-CSF (20 ng/ml) and RANKL (150 ng/ml) as in the previous experiments. Cells were plated on a layer of type I collagen. Six days later, when mature multinucleated osteoclasts were abundant, the plates were treated with collagenase to release the osteoclasts. These osteoclasts were then cultured on dentin slices +/-10 ng/ml rmIL-4 for 24hours. (B) Cells from wild type and STAT6 -/-mice, were isolated and culture as described above in panel A, and plated on hydroxyapatite coated discs +/-10 Bone marrow cells from wild type and STAT6 -/-animals were cultured with rmM -CSF (100 ng/ml) for three days. Subsequently, RANKL (150 ng/ml) +/-rmIL-4 (10 ng/ml) or rmTNF (20 ng/ml) +/-rmIL-4 (10 ng/ml) was added to the BMM , keeping the concentration of M-CSF (100 ng/ml) constant until the end of the experiment 3 days later. Cells were fixed and stained for TRAP activity. 
IL-4 Inhibition of TNF-induce osteoclastogenesis
